Company: HURA
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-179009
Chunk: 283

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-08-12
Form: S-1
Chunk 283
---
 C Preferred Stock and were entitled to the same dividend rights as each respective series.

The following table sets forth changes in outstanding Series C Agent Warrants:

|                                   |     | BalanceJune 30, 2024 |       |     | Number ofWarrants Expired |        |   |     | Balance,September 30, 2024 |   |     | Conversionprice$ |          |
|:----------------------------------|:----|:---------------------|------:|:----|:--------------------------|:-------|:--|:----|:---------------------------|:--|:----|:-----------------|---------:|
| Preferred SeriesC-1Agent Warrants |     |                      | 1,929 |     |                           | (1,929 | ) |     |                            | — |     |                  | 2,030.00 |
| Preferred SeriesC-2Agent Warrants |     |                      |   219 |     |                           | (219   | ) |     |                            | — |     |                  | 2,124.50 |
| Preferred SeriesC-3Agent Warrants |     |                      |   296 |     |                           | (296   | ) |     |                            | — |     |                  | 2,012.50 |
|                                   |     |                      | 2,444 |     |                           | (2,444 | ) |     |                            | — |     |                  |          |

9 Supplementary statement of cash flows information

The Company incurred the following non-cash investing and financing transactions (in thousands):

|                                                                                    |     | Three months endedSeptember 30, |       |     |       |     |
|                                                                                    |     |                           2024$ |       |     | 2023$ |     |
| Series C Preferred Stock common stock dividend (note 8)                            |     |                                 |    13 |     |       | 173 |
| Series A Preferred Stock cash dividend in accounts payable and accrued liabilities |     |                                 |     2 |     |       |   — |
| Conversion of Series C Preferred Stock to common stock (note 8)                    |     |                                 | 9,973 |     |       |  37 |
| Income taxes paid                                                                  |     |                                 |     — |     |       |   — |
| Interest paid                                                                      |     |                                 |     — |     |       |   — |

10 Financial instruments

The Company’s financial instruments are measured at